This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Guo F , Zhao X , Gill T , Zhou Y , Campagna M , Wang L , Liu F , Zhang P , DiPaolo L , Du Y , Xu X , Jiang D , Wei L , Cuconati A , Block TM , Guo JT , Chang J
An interferon-beta promoter reporter assay for high throughput identification of compounds against multiple RNA viruses
Antiviral Res. 2014 Apr 30;107 :56-65
AbstractVirus infection of host cells is sensed by innate pattern recognition receptors (PRRs) and induces production of type I interferons (IFNs) and other inflammatory cytokines. These cytokines orchestrate the elimination of the viruses but are occasionally detrimental to the hosts. The outcomes and pathogenesis of viral infection are largely determined by the specific interaction between the viruses and their host cells. Therefore, compounds that either inhibit viral infection or modulate virus-induced cytokine response should be considered as candidates for managing virus infection. The aim of the study was to identify compounds in both categories, using a single cell-based assay. Our screening platform is a HEK293 cell-based reporter assay where the expression of a firefly luciferase is under the control of a human IFN-beta promoter. We have demonstrated that infection of the reporter cell line with a panel of RNA viruses activated the reporter gene expression that correlates quantitatively with the levels of virus replication and progeny virus production, and could be inhibited in a dose-dependent manner by known antiviral compound or inhibitors of PRR signal transduction pathways. Using Dengue virus as an example, a pilot screening of a small molecule library consisting of 26,900 compounds proved the concept that the IFN-beta promoter reporter assay can serve as a convenient high throughput screening platform for simultaneous discovery of antiviral and innate immune response modulating compounds. A representative antiviral compound from the pilot screening, 1-(6-ethoxybenzo[d]thiazol-2-yl)-3-(3-methoxyphenyl) urea, was demonstrated to specifically inhibit several viruses belonging to the family of flaviviridae.
Notes1872-9096 Guo, Fang Zhao, Xuesen Gill, Tina Zhou, Yan Campagna, Matthew Wang, Lijuan Liu, Fei Zhang, Pinghu DiPaolo, Laura Du, Yanming Xu, Xiaodong Jiang, Dong Wei, Lai Cuconati, Andrea Block, Timothy M Guo, Ju-Tao Chang, Jinhong Journal article Antiviral Res. 2014 Apr 30;107C:56-65. doi: 10.1016/j.antiviral.2014.04.010.